RxDoctor Payments Data

Frances Israel

Family · Plymouth Meeting, PANPI 1508479668

Payments from drug & device makers

$364in general payments, 2019–2025

Across 7 payments — averaging $52.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$160
  • Amneal Pharmaceuticals LLC$117
  • Sumitomo Pharma America, Inc.$23
  • Sunovion Pharmaceuticals Inc.$23
  • Acadia Pharmaceuticals Inc$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$19

What the payments were for

  • Food & beverage$364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364 in reported general payments places this provider in the 50th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$160,917
Medicare patients
285
Services billed
1,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$28,546
ZenpepLipase/Protease/Amylase11$19,653
Sevelamer Hcl24$9,935
MyrbetriqMirabegron13$7,660
Clonidine13$4,277
VascepaIcosapent Ethyl12$4,087
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,503
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone12$2,182
BreynaBudesonide/Formoterol Fumarate11$2,073
Novolog FlexpenInsulin Aspart31$2,003
Atorvastatin Calcium123$1,674
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc17$1,642
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$1,277
Amlodipine Besylate94$1,212
Lorazepam83$1,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$117$94169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,717 family providers in Pennsylvania.

Other family in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →